statistiche ricercatore

AGENO, WALTER

Distribuzione geografica

Continente	#
NA - Nord America	40.888
EU - Europa	16.510
AS - Asia	5.236
Continente sconosciuto - Info sul continente non disponibili	55
SA - Sud America	33
OC - Oceania	14
AF - Africa	12
Totale	62.748

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	40.844
IT - Italia	6.387
UA - Ucraina	4.070
TR - Turchia	2.780
SE - Svezia	1.804
DE - Germania	1.405
VN - Vietnam	1.397
CN - Cina	945
IE - Irlanda	840
FI - Finlandia	706
GB - Regno Unito	578
FR - Francia	275
BE - Belgio	178
RU - Federazione Russa	131
EU - Europa	53
IN - India	50
CA - Canada	39
NL - Olanda	38
JP - Giappone	19
BR - Brasile	18
ES - Italia	13
CH - Svizzera	12
AU - Australia	11
PT - Portogallo	11
CL - Cile	9
RO - Romania	9
PL - Polonia	8
EG - Egitto	7
HK - Hong Kong	7
SG - Singapore	7
IL - Israele	6
AR - Argentina	5
AT - Austria	5
HU - Ungheria	5
MY - Malesia	5
CZ - Repubblica Ceca	4
GR - Grecia	4
LK - Sri Lanka	4
MK - Macedonia	4
BG - Bulgaria	3
DK - Danimarca	3
KW - Kuwait	3
MX - Messico	3
NZ - Nuova Zelanda	3
AE - Emirati Arabi Uniti	2
AL - Albania	2
EE - Estonia	2
HR - Croazia	2
ID - Indonesia	2
IR - Iran	2
KZ - Kazakistan	2
LI - Liechtenstein	2
NG - Nigeria	2
NO - Norvegia	2
RS - Serbia	2
SI - Slovenia	2
A1 - Anonimo	1
A2 - ???statistics.table.value.countryCode.A2???	1
BA - Bosnia-Erzegovina	1
BO - Bolivia	1
BY - Bielorussia	1
CR - Costa Rica	1
DZ - Algeria	1
KE - Kenya	1
KR - Corea	1
MD - Moldavia	1
MM - Myanmar	1
PH - Filippine	1
PR - Porto Rico	1
TH - Thailandia	1
TN - Tunisia	1
TW - Taiwan	1
Totale	62.748

Salva come PNG Salva come JPEG

Città	#
Fairfield	7.199
Milan	5.432
Woodbridge	4.802
Houston	3.519
Jacksonville	3.304
Ashburn	2.845
Seattle	2.740
Wilmington	2.601
Cambridge	2.461
Ann Arbor	2.425
Chandler	2.263
Izmir	1.393
Princeton	1.354
Dearborn	961
Dublin	836
Dong Ket	684
Nyköping	669
San Diego	399
San Mateo	308
Rome	275
Como	174
Brussels	171
Beijing	158
London	146
Düsseldorf	137
Hefei	124
Redmond	122
Philadelphia	118
Nanjing	95
Kocaeli	88
Kunming	81
Verona	80
Norwalk	75
Nanchang	56
Boardman	54
Jinan	50
Guangzhou	42
Falls Church	38
Besana In Brianza	33
Helsinki	33
Chiswick	30
Fuzhou	29
Redwood City	26
Chicago	23
Shenyang	22
Toronto	22
Zhengzhou	20
Islington	19
Ponte Lambro	19
Detroit	18
Phoenix	17
Tokyo	17
Wuhan	15
Xian	15
São Paulo	14
Changsha	13
Chengdu	13
Indiana	13
San Francisco	13
Auburn Hills	12
Hebei	12
Los Angeles	12
New York	12
Andover	11
Ningbo	11
Quzhou	11
Saint Petersburg	11
Shaoxing	11
Chongqing	10
Shanghai	9
Stockholm	9
Suresnes	9
Bangalore	8
Baotou	8
Hanover	8
Paris	8
Ralingen	8
Bergamo	7
Busto Arsizio	7
Florence	7
Hangzhou	7
New Bedfont	7
Amsterdam	6
Boydton	6
Casnate Con Bernate	6
Chaoyang	6
Dallas	6
Madrid	6
Montréal	6
Munich	6
Nanning	6
Torino	6
Varese	6
Bollate	5
Budapest	5
Cairo	5
Casorezzo	5
Edinburgh	5
Hanoi	5
Leawood	5
Totale	49.019

Salva come PNG Salva come JPEG

Nome	#
Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? Yes	244
Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study	227
Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis	222
A survey of thrombosis prophylaxis use in patients undergoing arthroscopic surgery	218
Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature	206
Risk factors for suboptimal efficacy of 3-factor prothrombin complex concentrates in emergency vka anticoagulation reversal	204
Risk of recurrence of unusual site venous thromboembolism	203
Novel oral anticoagulants for the prevention of venous thromboembolism in surgical patients	184
Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome	183
Oral anticoagulant therapy in patients with mechanical heart valve and intracranial haemorrhage. A systematic review	181
Relationship between regulatory T cells subsets and lipid profile in dyslipidemic patients: A longitudinal study during atorvastatin treatment	181
Abdominal obesity and the risk of recurrent deep vein thrombosis	178
Breadth of complications of long-term oral anticoagulant care	178
Optimal treatment duration of venous thrombosis	176
incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio.	175
The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry	173
Patient selection for thromboprophylaxis in medical inpatients	171
Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry	171
Management of recurrent venous thromboembolism in cancer patients	171
Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy: A randomized, controlled trial	169
Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study	169
Diagnostic accuracy of lung ultrasound for pulmonary embolism: a systematic review and meta-analysis.	168
Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): An international, prospective, non-interventional study	168
Diagnosis and management of venous thromboembolism: Results of a survey on current clinical practice	167
Prognostic stratification of chronic heart failure in elderly population: are cardiopulmonary tests and BNP really valuable?	166
Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism.	165
Role of ABO blood group and of other risk factors on the presence of residual vein obstruction after deep-vein thrombosis	164
Venous thromboembolism: “…an ounce of prevention is worth a pound of cure”	163
Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature	162
Association between ABCG2 and ABCB1 genes and warfarin stability: a case-control study	162
Unsuspected pulmonary embolism in cancer patients: a narrative review with pooled data	162
Prevalence and Clinical History of Incidental, Asymptomatic Pulmonary Embolism: A Meta-Analysis	162
Adverse events associated with the use of direct-acting oral anticoagulants in clinical practice: Beyond bleeding complications	162
Update on the diagnosis and management of pulmonary embolism	161
Effect of thromboprophylaxis with anticoagulant drugs on the incidence of arterial thrombotic events in medical inpatients: a systematic review	159
Venous ischemic syndromes	159
Treating patients with cancer and acute venous thromboembolism	158
Oral rivaroxaban for symptomatic venous thromboembolism	157
Prevention and treatment of venous thromboembolism	157
Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism	157
Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation	157
Venous and arterial thrombosis in patients with HIV infection	156
Pulmonary Embolism Severity Index Accurately Predicts Long-Term Mortality Rate In Patients Hospitalized For Acute Pulmonary Embolism	156
Exaggerated initial response to warfarin following heart valve replacement	155
Real-world economic burden of venous thromboembolism and antithrombotic prophylaxis in medical inpatients	155
Warfarin interactions with antibiotics in the ambulatory care setting	154
Management of incidental splanchnic vein thrombosis in cancer patients	154
Duration of anticoagulation after venous thromboembolism in real world clinical practice	154
A clinical score to rule out the concomitant presence of deep vein thrombosis in patients presenting with superficial vein thrombosis: The ICARO study	154
Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: A multicenter cohort study	154
Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy	154
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty	153
Managing challenging patients with venous thromboembolism: A practical, case-based approach	153
Venous thromboembolism: Past, present and future	153
Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation	151
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism	151
Management of primary care patients with suspected deep vein thrombosis: use of a therapeutic dose of low-molecular-weight heparin to avoid urgent ultrasonographic evaluation.	150
Applying EBM in clinical practice	149
A case report and literature review of portal vein thrombosis associated with Cytomegalovirus infection in immunocompetent patients	149
Statins and secondary prevention of ischemic and hemorrhagic stroke	148
Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study	148
Direct oral anticoagulants in rare venous thrombosis	148
Diagnostic accuracy of magnetic resonance imaging in patients with suspected pulmonary embolism: A bivariate meta-analysis	148
In vitro effects of Apixaban on 5 different cancer cell lines	148
Perioperative anticoagulation for patients with mechanical heart valves: a survey of current practice.	147
Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis. The ”CANCER DACUS” study	147
Gender Difference in Efficacy and Safety of Nonvitamin K Antagonist Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation or Venous Thromboembolism: A Systematic Review and a Meta-Analysis of the Literature	147
Emergency reversal of anticoagulation with vitamin K antagonists with 3-factor prothrombin complex concentrates in patients with major bleeding	146
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE	146
Prevention and treatment of venous thromboembolism in patients with solid brain neoplasms: results of a survey among Italian physicians	146
Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis	145
When and how to use antidotes for the reversal of direct oral anticoagulants: Guidance from the SSC of the ISTH	145
Major Bleeding and Case Fatality Rate with the Direct Oral Anticoagulants in Orthopedic Surgery: A Systematic Review and Meta-Analysis	145
Predictors of residual venous obstruction after deep vein thrombosis of the lower limbs: a prospective cohort study	144
Dabigatran in clinical practice: Contemporary overview of the evidence	144
Analysis of an algorithm incorporating limited and whole-leg assessment of the deep venous system in symptomatic outpatients with suspected deep-vein thrombosis (PALLADIO): a prospective, multicentre, cohort study	143
The prevention and treatment of venous thromboembolism in pregnancy	143
Presence of residual thromboemboli at least six months after a first episode of symptomatic pulmonary embolism: do perfusion scintigraphy and angio-computed tomography agree?	142
Pros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants	142
Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature	142
Intracranial bleeding risk after minor traumatic brain injury in patients on antithrombotic drugs	142
The role of inherited thrombophilia in patients with isolated pulmonary embolism: a systematic review and a meta-analysis of the literature	141
Risk–Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies	141
Low ankle-brachial index predicts an adverse 1-year outcome after acute coronary and cerebrovascular events	141
The 8th American college of chest physicians guidelines - A perspective on venous thromboembolism guidelines	141
Pulmonary embolism prognostic factors and length of hospital stay: A cohort study	141
Brain natriuretic peptide and preclinical chronic thromboembolic pulmonary hypertension.	140
Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage	140
Spotlight on real-world evidence for the treatment of DVT: XALIA	140
Statin use and bleeding risk during vitamin K antagonist treatment for venous thromboembolism: A multicenter retrospective cohort study	139
Statins for acute ischemic stroke	139
NOACs for treatment of venous thromboembolism in clinical practice	139
The role of thrombolytic therapy in pulmonary embolism	138
Epidemiology and pathophysiology of venous thromboembolism: similarities with atherothrombosis and the role of inflammation	138
Guidance for the management of venous thrombosis in unusual sites	138
Low-molecular -weight heparin in pregnancies after ART -A retrospective study-	138
Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism: An analysis of the randomised, double-blind HOKUSAI VTE trial	138
Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide	138
Prevention of in-hospital VTE: why can't we do better?	137
JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia.	137
Totale	15.815

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	176.809
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	176.809

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2018/2019	7.212	0	0	1.091	26	13	21	54	496	73	809	1.791	2.838
2019/2020	14.687	718	679	753	2.942	986	1.555	2.116	1.734	1.148	917	259	880
2020/2021	13.672	231	1.104	1.563	1.769	973	1.398	543	1.229	1.505	804	954	1.599
2021/2022	6.835	758	872	355	182	403	377	337	376	387	1.268	644	876
2022/2023	7.039	828	260	432	659	517	1.583	83	832	1.047	308	241	249
2023/2024	6.231	2.157	2.276	1.798	0	0	0	0	0	0	0	0	0
Totale													63.595